Genius Sports Limited Announces the Reduced Exercise Price in the Previously Announced Consent Solicitation
Genius Sports Limited (NYSE:GENI) announced a reduction in the exercise price of its outstanding warrants from $11.50 to $3.1816 as part of a consent solicitation. This was communicated to warrant holders on December 20, 2022. Additionally, if warrant holders do not exercise their warrants by the expiration date, they will automatically exercise at an Automatic Exercise Price of $3.2933, yielding 0.234 ordinary shares per warrant. The warrants are set to expire on April 20, 2026. The company is working with BofA Securities for solicitation and has filed necessary documents with the U.S. SEC.
- Reduced exercise price from $11.50 to $3.1816, incentivizing warrant exercises.
- Potentially successful consent solicitation could facilitate automatic exercises at favorable prices.
- If the Warrant Amendment is not approved, the warrants will retain unfavorable terms.
- The number of shares received per warrant at the Automatic Exercise Price is 10% less than at the Reduced Exercise Price.
Pursuant to a notice circulated to warrant holders on
The Reduced Exercise Price of the warrants is
Pursuant to the consent solicitation, the Company’s Warrant Agreement will be amended so that any warrants not exercised by a holder thereof on or prior to the expiration date shall be exercised automatically on the holder’s behalf on the first trading day following the expiration date on a cashless basis at the exercise price that is
Therefore, if the consent solicitation is successful, the warrant holders who do not elect to exercise their warrants on or prior to the expiration date will have their warrants exercised at the Automatic Exercise Price of
If the Warrant Amendment is not approved and such condition is not waived, the warrants will retain their current terms and any exercises of warrants by holders at the Reduced Exercise Price will not be consummated and holders will be returned their warrants. The warrants currently have an exercise price of
The Company has engaged
Important Additional Information has been Filed with the
In connection with the consent solicitation, the Company has filed with the
This announcement is for informational purposes only and shall not constitute an offer to purchase or a solicitation of an offer to sell the warrants or an offer to sell or a solicitation of an offer to buy any ordinary shares in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of any such state. The consent solicitation is being made only through the Schedule TO and prospectus and the complete terms and conditions of the consent solicitation are set forth in the Schedule TO and prospectus. Copies of the Schedule TO and prospectus will be available free of charge at the website of the
Holders of the warrants are urged to read the Schedule TO and prospectus carefully before making any decision with respect to the consent solicitation because they contain important information, including the various terms of, and conditions to, the consent solicitation.
None of the Company, any of its management or its board of directors, or the solicitation agent, the transfer agent or the information and tabulation agent makes any recommendation as to whether or not holders of warrants should consent to the Warrant Amendment in the consent solicitation.
About
Forward-Looking Statements
This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve significant risks and uncertainties. All statements other than statements of historical facts are forward-looking statements. These forward-looking statements include information about our possible or assumed future results of operations or our performance. Words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “estimates,” and variations of such words and similar expressions are intended to identify such forward looking statements. Forward-looking statements in this press release may include, for example, statements about the consummation of the consent solicitation, the entry into the Warrant Amendment and the effects of the consent solicitation on our capital structure. Although the Company believes that the forward-looking statements contained in this press release are based on reasonable assumptions, you should be aware that many factors could affect our actual financial results or results of operations and could cause actual results to differ materially from those in such forward-looking statements, including but not limited to: our ability to successfully complete the consent solicitation; the effect of COVID-19 on our business; risks related to our reliance on relationships with sports organizations and the potential loss of such relationships or failure to renew or expand existing relationships; fraud, corruption or negligence related to sports events, or by our employees or contracted statisticians; risks related to changes in domestic and foreign laws and regulations or their interpretation; compliance with applicable data protection and privacy laws; pending litigation and investigations; the failure to protect or enforce our proprietary and intellectual property rights; claims for intellectual property infringement; our reliance on information technology; and other factors included under the heading “Risk Factors” in our filings with the
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained herein, to reflect any change in our expectations with respect to such statements or any change in events, conditions or circumstances upon which any statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005425/en/
Media
+1 (202) 766-4430
chris.dougan@geniussports.com
Investors
+1 (954)-554-7932
brandon.bukstel@geniussports.com
Source:
FAQ
What is the new exercise price for Genius Sports warrants?
What happens if warrant holders do not exercise their warrants by the expiration date?
When do the warrants for Genius Sports expire?
What is the benefit of exercising warrants at the Reduced Exercise Price?